0001001316 false 0001001316 2019-11-12 2019-11-12


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________
 
FORM 8-K
_____________
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): November 12, 2019
 
TG Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
  
Delaware
(State or Other Jurisdiction
of Incorporation)
001-32639
 (Commission File Number)
36-3898269
(IRS Employer Identification No.)
 

2 Gansevoort Street, 9th Floor
New York, New York 10014
(Address of Principal Executive Offices)
 
(212) 554-4484
(Registrant's telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act.
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
 
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
 
Title of Class
Trading Symbol(s)
Exchange Name
Common Stock, par value $0.001
TGTX
Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


 
Item 2.02. Results of Operations and Financial Condition.
 
On November 12, 2019, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results of operations for the three and nine months ended September 30, 2019. The Company will host an investor conference call today, November 12, 2019, at 8:30am ET, during which the Company will provide a brief overview of its third quarter financial results and provide a business outlook for the remainder of 2019. A copy of such press release is being furnished as Exhibit 99.1.
 
Item 9.01 Financial Statements And Exhibits.
 
(d)          Exhibits.
 
99.1
Press release issued by TG Therapeutics, Inc., dated November 12, 2019.
 
 
 
 
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
TG Therapeutics, Inc.
(Registrant)
 
 
 
 
 
Date: November 12, 2019
By:  
/s/ Sean A. Power
 
 
 
Sean A. Power 
 
 
 
Chief Financial Officer